Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

News Conference News ACC 2023

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

March 10, 2023

TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR

News Conference News ACC 2023

TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR

March 04, 2023

What’s Going to Be Hot at ACC/WCC 2023?

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

February 27, 2023

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

April 04, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry

News Conference News ACC 2020

Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry

Michael O'Riordan

March 19, 2020

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

Heart Failure and Secondary Mitral Regurgitation:Echocardiographic Outcomes from the COAPT trial

Presentation ACC 2019

Heart Failure and Secondary Mitral Regurgitation: Echocardiographic Outcomes from the COAPT trial

Presenter: Federico M. Asch

March 17, 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

March 11, 2019

PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO

News Conference News ACC 2018

PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO

March 15, 2018

Top Stories in Cardiology, March 2017

Podcast Heart Sounds ACC 2017

Top Stories in Cardiology, March 2017

March 29, 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

News Conference News ACC 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

Michael O'Riordan

March 24, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.